Guideline Recommendations for Initiating Inhaled Corticosteroids in Young Children with Asthma

Indications for Controller Therapy

Budesonide inhalation suspension is the only FDA‑approved inhaled corticosteroid for children younger than 4 years (approved for ages 1–8 years). This provides a regulator‑cleared controller option for a 4‑year‑old with asthma‑related nocturnal cough. 6
Fluticasone dry‑powder inhaler is FDA‑approved for children aged 4 years and older, offering an alternative device‑based controller for this age group. 6

Medium‑dose inhaled corticosteroids (e.g., budesonide 0.5 mg twice daily) have been shown in clinical studies to be effective in controlling symptoms in children under 5 years of age. The studies supporting this dosing regimen were published in the Journal of Allergy and Clinical Immunology (2002). 7
Multiple investigations reported that inhaled corticosteroids are the most effective controller therapy for pediatric asthma by suppressing airway inflammation. These findings are derived from the same 2002 series of studies. 8